

EQA round: AP1/26 - Antithrombotic Agents

Deadline: 27.3.2026

Setup: groups - M (measurement principle); minimal size of the groups n = 5

RoM = robust average

AV = assigned value

D_{max} = acceptable difference

SD = standard deviation

CVP = consensus of all participants

LL = lower limit

CV = coefficient of variation

U_{AV} = expanded uncertainty of the assigned value (k = 2)

UL = upper limit

N_{tot} = total number of the resultsN_{eva} = number of the results assessedN_{out} = number of the results removed before calculationN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL					
Set 1																
(108) Apixaban	[µg/L]				61									61	60	98
Sample A1		67	6,6	9,9	61		CVP	67	2,1	25%	50,2	83,8		61	60	98
(2) Chromogenic substrates		66,9	6,6	9,8	58	0								58		
Other					3	0								3		
							3x 1									
Sample B1		274	14	5,2	61		CVP	274	4,5	25%	205	343		61	61	100
(2) Chromogenic substrates		274	15	5,4	58	0								58		
Other					3	0								3		
							3x 1									
Set 2																
(109) Dabigatran	[µg/L]				39									39	37	95
Sample A2		46,2	5,3	11	39		CVP	46,2	2,1	30%	32,3	60,1		39	37	95
(1) Coagulometer		44,6	3,6	8,1	19	0								19		
(2) Chromogenic substrates		48,5	6,8	14	20	1								20		
Sample B2		183	13	6,9	39		CVP	183	5	30%	128	238		39	39	100
(1) Coagulometer		185	18	9,8	19	0								19		
(2) Chromogenic substrates		183	8,1	4,4	20	0								20		
Set 3																
(110) Rivaroxaban	[µg/L]				64									64	62	97
Sample A3		81,5	4,9	6	64		CVP	81,5	1,5	25%	61,1	102		64	63	98
(2) Chromogenic substrates		81,3	4,9	6,1	61	0								61		
Other					3	0								3		
							3x 1									
Sample B3		318	19	6	64		CVP	318	5,9	25%	238	398		64	63	98
(2) Chromogenic substrates		318	19	5,9	61	0								61		
Other					3	0								3		
							3x 1									